Key Highlights
- 2026 Revenue guidance cut to £180m-£200m from £220m-£240m on client order deferrals
- Sales pipeline grew to approximately $713m, up around 30% year on year
- Signed 17 new clients in H1, already more than 30% above all of 2025
- Shares fell more than 24% in a single session, the steepest fall since June 2013
- Durham, North Carolina Facility delayed roughly six months but now back on track
- Medium-term targets maintained: 25-30% revenue growth in 2027 and around £500m of revenue by 2030
Few updates capture the tension inside a scaling contract manufacturer as neatly as the one Oxford Biomedica (LSE:OXB) delivered on 7 August 2026. The Oxford-based cell and gene therapy specialist reported its strongest-ever run of new client signings alongside a pipeline it values at roughly $713m, while simultaneously lowering its 2026 revenue expectations by around £40m. The market focused on the downgrade: the shares tumbled more than 24%, their steepest one-day fall since June 2013. For a Business that has spent recent years repositioning from a therapeutics developer into a pure-play contract development and Manufacturing organisation (CDMO), the episode is a reminder that momentum and lumpiness can coexist.
What Has Happened?
In its half-year trading update, Oxford Biomedica said clients had deferred orders and pushed back programme timelines, in several cases because of changes to their own clinical strategies or approval pathways. Management singled out one larger client's shift in procurement strategy as a key driver. Compounding the timing issues, the company said its Durham, North Carolina facility had slipped by roughly six months, delaying revenue that had been expected to contribute in the current year, though it described the site as now back on track.
As a result, the board cut full-year 2026 revenue guidance to £180-200m, down from a previous range of about £220-240m. The reported EBITDA Margin for 2026 is now expected in the low-single-digit percentages, or mid-single digits excluding one-off costs. Crucially, management left its medium-term framework intact, reiterating a target of 25-30% revenue growth in 2027 and an ambition of around £500m of revenue by 2030.
The Numbers Investors Need to Know
First-half revenue rose about 9% to roughly £80m. The company signed 17 new clients in the period, already more than 30% above its full-year 2025 total, and put its new-business pipeline at approximately $713m, up around 30% year on year. The revenue Backlog stood at about £193m, with contracted client orders of roughly £97m and about £165m of 2026 revenue already covered by orders at the time of the update.
Balance-sheet figures show the cost of scaling. Gross cash was £75m at 30 June 2026, down from £97m at the end of 2025, while net cash fell to £21m from £55m over the same period. The pace of that drawdown, roughly £22m of gross cash and £34m of net cash in six months, is a reminder that a CDMO in build-out mode consumes Working Capital even when Demand indicators look healthy. It also sharpens the read on guidance: the roughly £165m of orders already covering 2026 sits below the new £180-200m range, so hitting even the reduced target still depends on converting further pipeline into firm orders during the second half. The £193m backlog and £97m of contracted orders provide a cushion, but the gap between covered revenue and the guidance midpoint is where the execution risk now lives. Longer term, management continues to guide towards double-digit EBITDA margins in 2027 and an EBITDA margin approaching 30% over time. Interim results are scheduled for 22 September 2026.
Why This Matters
The CDMO model lives and dies on capacity utilisation and order visibility. When a small number of large clients account for a meaningful share of near-term revenue, their programme decisions ripple straight through to the manufacturer's top line. That is precisely what has happened here: the demand signal, as measured by pipeline and new logos, is improving, but the conversion of that demand into billed revenue has slipped to the right. For shareholders, the downgrade tests the credibility of a turnaround that had been gathering pace, and it raises the question of how much of 2026's shortfall is genuinely deferred rather than lost.
What Is Driving the Story?
Two forces are pulling in opposite directions. On the positive side, structural demand for outsourced viral-vector and cell and gene therapy manufacturing remains firm, evidenced by the record client wins and a pipeline that has grown despite a cautious biotech funding backdrop. On the negative side, Oxford Biomedica's customers, many of them clinical-stage developers, are themselves subject to trial readouts, financing constraints and regulatory timelines that the CDMO cannot control. The Durham delay adds a self-inflicted element, though a six-month slip on a complex new facility is not unusual. Chief executive Dr Frank Mathias framed the update as continued strong underlying demand set against near-term ordering volatility.
What Could Drive the Shares Next?
The 22 September interim results are the immediate catalyst, offering a fuller picture of margins, cash burn and the phasing of the deferred orders into 2027. Beyond that, investors will watch for confirmation that the Durham site is commissioned on the revised schedule, for evidence that the deferred programmes are being reactivated, and for the pace at which the $713m pipeline converts into signed contracts. Any commentary on the concentration of revenue among the largest clients would also help the market gauge how repeatable this year's disruption might be. Progress towards the 2027 growth target will ultimately determine whether the long-term thesis survives intact.
Risks Investors Should Watch
The most obvious risk is that "deferred" revenue proves harder to recover than management expects, particularly if client clinical programmes are cancelled rather than delayed. Client concentration magnifies that exposure. Falling cash balances, while still comfortable, reduce the margin for error if the Top Line disappoints again. Execution risk at Durham, currency movements, and the broader health of biotech funding all feed into demand. Finally, having reset guidance once, the board has raised the bar for delivering against its remaining 2026 range and its ambitious 2030 target.
The Bottom Line
Oxford Biomedica's (LSE:OXB) update was a study in mixed messages: record client wins and a growing $713m pipeline on one hand, a chunky guidance cut and shrinking cash on the other. The market's verdict, a more than 24% fall, reflects scepticism about near-term execution rather than the long-term opportunity, which management insists is undimmed. The Investment case now hinges on whether deferred orders return, whether Durham comes on stream as promised, and whether the impressive pipeline can be converted into dependable, less lumpy revenue. September's interim results should offer the first real test.






Please wait processing your request...